RARE earnings: a positive outcome, +8.3%

On January 12, 2026, Ultragenyx Pharmaceutical Inc. reached its earnings. The result was a positive outcome, and the stock moved +8.3% in the window around the event. It had already run -37.9% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.